Rainbow BioSciences’ (OTCBB:RBCC) new partner, Nano3D Biosciences (N3D), is working on a new prototype that could make mass three-dimensional cell culturing easier than ever before. The company is close to producing its first 96-well Bio-Assembler. The new prototype will be a significant increase in scale over N3D’s current Bio-Assembler products, which are currently available in single-well, six-well and 24-well versions. The 96-well prototype is designed to allow much higher throughput productivity, making the system ideal for use in major laboratories and large-scale projects. With RBCC’s help, n3D plans to aggressively market the new device to labs and researchers around the world engaged in drug discovery, toxicology screenings, stem cell research and other research endeavors. The Bio-Assembler’s revolutionary functionality allows it to produce accurate, 3D representations of in vivo tissues in roughly the same time needed to produce 2D cell cultures. The system uses magnetic nanoparticles to levitate cells, allowing them to grow in three dimensions rather than flat on the bottom of a petri dish. The easy-to-use technology is compatible with any media, diagnostic technique or cell type. With N3D’s Bio-Assembler poised to dramatically reduce the development timeline for new life-saving drug therapies, Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., acquired an equity interest in N3D last month. RBCC believes that this acquisition has the company well-positioned to participate in the potentially impressive upside in store for n3D. For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN). About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [ www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.